Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hudecek

Showing results (11-20 of 138) with videos related to

Pageof 14
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 26, 2024
Accelerating CAR-T Cell Therapies with Small-Molecule InhibitorsKatrin Mestermann, Andoni Garitano-Trojaola, Michael Hudecek
Current Opinion in Oncology|July 14, 2020
New targets and technologies for CAR-T cellsFabian Freitag, Marius Maucher, Zeno Riester, et al.
Journal of Hepatology|June 22, 2025
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseasesElmar Jaeckel, Scott L Friedman, Michael Hudecek, et al.
Journal of Visualized Experiments : Jove|October 21, 2024
Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon SystemMaximilian Bauser, Hermann Einsele, Jürgen Löffler, et al.
Expert Review of Hematology|November 19, 2010
Adoptive T-cell therapy for B-cell malignanciesMichael Hudecek, Larry D Anderson, Tetsuya Nishida, et al.
Current Opinion in Immunology|July 24, 2012
Engineered T cells for anti-cancer therapyCameron J Turtle, Michael Hudecek, Michael C Jensen, et al.
Frontiers in Immunology|November 15, 2021
T-Cell Metabolism in Graft <i>Versus</i> Host DiseaseFranziska Karl, Michael Hudecek, Friederike Berberich-Siebelt, et al.
Oncology Research and Treatment|March 16, 2025
Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid MalignanciesJessica Peter, Fabio Toppeta, Alexandre Trubert, et al.
Current Opinion in Oncology|August 16, 2020
Overcoming key challenges in cancer immunotherapy with engineered T cellsSilvia Arcangeli, Katrin Mestermann, Justus Weber, et al.
Advances in Cell and Gene Therapy|November 14, 2018
CAR T cells targeting α<sub>v</sub>β<sub>3</sub> integrin are effective against advanced cancer in preclinical modelsLars Wallstabe, Andreas Mades, Silke Frenz, et al.
Pageof 14

Showing results (11-20 of 138) with videos related to

Sort By:
Pageof 14
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 26, 2024
Accelerating CAR-T Cell Therapies with Small-Molecule InhibitorsKatrin Mestermann, Andoni Garitano-Trojaola, Michael Hudecek
Current Opinion in Oncology|July 14, 2020
New targets and technologies for CAR-T cellsFabian Freitag, Marius Maucher, Zeno Riester, et al.
Journal of Hepatology|June 22, 2025
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseasesElmar Jaeckel, Scott L Friedman, Michael Hudecek, et al.
Journal of Visualized Experiments : Jove|October 21, 2024
Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon SystemMaximilian Bauser, Hermann Einsele, Jürgen Löffler, et al.
Expert Review of Hematology|November 19, 2010
Adoptive T-cell therapy for B-cell malignanciesMichael Hudecek, Larry D Anderson, Tetsuya Nishida, et al.
Current Opinion in Immunology|July 24, 2012
Engineered T cells for anti-cancer therapyCameron J Turtle, Michael Hudecek, Michael C Jensen, et al.
Frontiers in Immunology|November 15, 2021
T-Cell Metabolism in Graft <i>Versus</i> Host DiseaseFranziska Karl, Michael Hudecek, Friederike Berberich-Siebelt, et al.
Oncology Research and Treatment|March 16, 2025
Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid MalignanciesJessica Peter, Fabio Toppeta, Alexandre Trubert, et al.
Current Opinion in Oncology|August 16, 2020
Overcoming key challenges in cancer immunotherapy with engineered T cellsSilvia Arcangeli, Katrin Mestermann, Justus Weber, et al.
Advances in Cell and Gene Therapy|November 14, 2018
CAR T cells targeting α<sub>v</sub>β<sub>3</sub> integrin are effective against advanced cancer in preclinical modelsLars Wallstabe, Andreas Mades, Silke Frenz, et al.
Pageof 14